Objectives: To evaluate the outcomes of rotational atherectomy for heavily-calcified side branches of coronary bifurcation lesions.
| INTRODUCTION
Side branch (SB) occlusion following bifurcation lesion interventions has an incidence rate of 10-20%, [1] [2] [3] [4] [5] [6] [7] which mostly due to carina shift, plaque shift/redistribution, vessel dissection or spasm, 2, 8, 9 and can be predicted by various factors. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Mostly, SB occlusion is not associated with an increase in mortality but rather in morbidity. 4, 5, 7, 9 A number of methods are used for SB protection during bifurcation lesion treatment. These include SB wiring, predilatation, jailed SB balloon, and two-stent strategies. 11 However, in the cases of extremely calcified SB, device-uncrossable or-undilatable, the indispensable option is rotational atherectomy (RA).
RA is considered the standard treatment of heavily calcified coronary lesions, even for unprotected left main, 12,13 long lesions, 14 or those with acute coronary syndrome. 15, 16 However, very few studies have been reported on the use of RA for treating SB, especially for heavily-calcified and complex true bifurcation lesions even in the contemporary drug-eluting stent (DES) era. The main reason is that SB RA is expected to be associated with high procedural risks, and scrupulous technique is warranted. First, SB is typically shorter than MV and it has multiple bends, providing only a shallow landing zone for the SB RotaWire. The wire may perforate the vessel if it went too deep or it might slip out from the SB if too shallow. Second, the SB RA cannot be completed if preceding RA for main vessel results in either unstable hemodynamics or severe dissections at the bifurcation.
This retrospective observational study was therefore aimed to explore the feasibility and outcomes of RA for extremely calcified, deviceuncrossable or-undilatable SB of complex heavily-calcified bifurcation lesions. Figure 1 together with a supplementary video clip (Video S1).
After stent implantation, we continued dual-antiplatelet therapy with 3 | RESULTS
| Baseline characteristics of patients
A total of 293 patients were studied: one group (244 patients, aged 74.5 ± 11.5 years, male 64.3%) underwent MV only RA (the SB-MV + RA group) and another group (48 patients, aged 73.8 ± 11.7
years, male 64.6%) underwent SB RA (SB + MV ± RA group) for 49 side branches. These two groups had similar demographic findings, except the SB-MV + RA group showed higher levels of serum creatinine (2.7 ± 2.8 mg/dL vs 1.8 ± 1.7 mg/d, P = 0.005) and had more cases with RCA and fewer cases with LAD RA (Table 1) . Most of the RA procedures were performed through the femoral approach and using 7F guide catheters in both groups.
| PCI Characteristics and QCA findings of SB RA cases
In the SB + MV ± RA group, 30 (62.5%) patients underwent RA for both SB and MV (the SB + MV + RA subgroup). The remaining 18 (37.5%) patients underwent SB only RA (SB + MV-RA subgroup), in which one patient underwent both diagonal and obtuse marginal branches RA (Table 2 ). In contrast to the SB + MV−RA subgroup, the SB + MV + RA subgroup had higher SYNTAX scores (31.8 ± 12.0 vs 21.0 ± 11.7, | 489 P = 0.004), more Ambrose 2 lesions in the MV (100% vs 27.8%, P < 0.001), and more stenting of MV (100% vs 33.3%, P < 0.001). The SB + MV + RA subgroup also had more applications of IABP (26.7% vs 0%, P < 0.001), implicating more complex procedures in this subgroup.
In contrast, patients in the SB + MV−RA subgroup had longer SB lesion lengths (23.0 ± 11.3 mm vs 15.6 ± 9.1 mm, P = 0.026), more uses of 1.5 mm burr for SB (6.7% vs 44.4%, P = 0.007), more bail-out indication for RA (55.6% vs 6.7%, P = 0.001) and a trend toward more SB stenting (38.9% vs 16.7%, P = 0.085). Despite such differences, all RA procedures in the two subgroups were successfully completed and associated with similar procedural and fluoroscopic durations and contrast doses.
| Procedure outcomes of SB RA
The procedure outcomes, in terms of in-procedure hemodynamic support, acute no flow, cardiogenic shock, emergent CABG or wire fracture of the group SB + MV ± RA were comparable with those of group SB-MV + RA (Table 3) . No patient in any of the two groups had died during the procedure. In the SB + MV ± RA group, the incidence of SB perforation was significantly higher than that of SB-MV + RA group (6.3% vs 0.8%, P = 0.041). Among the three patients with perforations, all were successfully managed during the index procedure without significant sequela. The incidence of acute contrast-induced nephropathy (CIN) was also higher in the SB + MV ± RA group compared with SB-MV + RA group (8.2% vs 2.5%, P = 0.045).
| Long-term outcomes of SB RA
After an average follow-up period of 25.1 months, the MACE rate for patients underwent SB + MV ± RA was 27.1 %, mostly (16.7%) driven by target revascularization. No difference was found in MACE rate between the two subgroups (SB + MV + RA and SB + MV−RA), despite lower rates of total death (5.6% vs 36.7%, P = 0.04) or CV death (5.6% vs 13.3%, P = 0.023) in the SB + MV−RA subgroup (Table 4) .
| DISCUSSION
In summary, we found in this retrospective observational study that RA was feasible for heavily calcified, device-uncrossable, or deviceundilatable SB lesions of calcified non-LM coronary bifurcation lesions in the DES era. It had a high success rate with quite acceptable procedural and long-term MACE outcomes. SB RA, however, was found to associate more often with SB perforations and acute CIN than the MV only RA. While IABP support was equally applied to both SB RA and MV only RA, SB plus MV RA subgroup required in-procedural IABP support more often than that of SB only RA subgroup. In the SB only RA subgroup, more cases required SB stenting but fewer required MV stenting compared with those in the SB plus MV RA subgroup. The results of our study supported that SB RA is an important and effective means to achieve SB revascularization in modern practice.
SB preservation is a critical issue in the intervention of true bifurcation lesions. In the time of bare metal stent (BMS) and even in the era of early drug-eluting stent (DES), SB RA is mainly used for debulking of large plaques, but not for heavy calcification. [17] [18] [19] [20] RA was first introduced two decades ago to treat bifurcation lesions with huge plaque burden in a "plaque debulking" manner rather than "plaque modification" for heavily calcified lesions as in the current study.
17,18
Although 8-10 Fr sheaths and guide catheters were required to accommodate large rotablation burrs, the early experience of Rihal et al in 1998 proved the feasibility of RA for bifurcation lesions with acceptable procedural success rate. 17 In the same year, Dauerman et al's study showed that SB plaque debulking by mechanical atherectomy and subsequent balloon angioplasty has significant favorable impact on procedure success and target-vessel revascularization as compared to balloon angioplasty only. 18 However, only 6 of their 40 patients (15%) in the debulking group used RA and larger burr sizes (60 to 80% of reference vessel diameter) was chosen. Nageh et al studied 31 patients undergoing SB RA for bifurcation lesions in a manner of kissing balloon technique and bail-out stenting. 19 They found better acute gain and less restenosis compared to balloon angioplasty alone, but "true" bifurcation only accounted for 59% of all lesions. These three studies were carried out in the BMS era in which in-stent restenosis (ISR) could be a major concern. The SB RA was used mostly to reduce plaque burden, SB jails and SB restenosis at that time, and none of them had targeted at preserving heavily-calcified challenging SB lesions. were heavily calcified and none of the SB RA was done in a bail-out manner, implying a less serious or challenging clinical situation. Finally, our patients had more diabetes mellitus, higher levels of serum creatinine, and more multivessel diseases. These factors were negative contributors for long-term outcomes of RA.
14,21-24
Despite a higher incidence of MACE in our study relative to Ito's report, our results were comparable with other studies on RA in deployment of the 2nd generation DES. The MACE rate at two-year follow-up in a single-center study in Japan and two large multicenter registries, ADAPT-DES and ROTATE, was 20.3%, 25 22.1%, and 24.7%, respectively. 26, 27 In our study, the MACE rate at an average follow-up period of 25.1 months was 27.1% which was quite acceptable given the high clinical risks and the complex coronary lesions necessitating SB RA.
The higher non-cardiovascular death rate of 14.6% during follow-up in our study (compared to that of 2.7 to 7% at 2-year follow-up in the Japan cohort 25 and the ADAPT-DES registry 26 ) suggested that our patients had higher fragility with multiple comorbidities. To our knowledge, our study is the largest cohort to date for SB RA and the only study specifically addressing RA of heavily calcified, balloon-uncrossable orundilatable SB of heavily-calcified true bifurcation lesions.
Balloon dilatation with bail-out RA has been adopted as the default strategy since the landmark ROTAXUS trial 28, 29 was published, which showed no clinical benefits with routine RA up to two years. However, the percentage of primary RA in the side-branch plus main-vessel rotablation group (SB + MV + RA) in our study was relatively high of 93.3%. It was based on our team's experience that these SB had to be heavy calcification in the SB in these cases were also 100%. From our experience, two-stent technique which was done in 16.7% of the cases could never be realized if no debulking of these SB was done. These were the reasons that we did SB RA primarily in these super-selected cases, for which traditional PCI could be time-consuming, fruitless, or complication-generating. Also, our strategy was justified by none of the treated SB was lost during procedure. Therefore, RA of SB in the SB + MV + RA cases done in the primary fashion did not equate conventional PCI would work in these cases.
| LIMITATION
There are several limitations of our study. First, the retrospective design is inherently subject to selection bias and other confounding factors. However, this study did reflect the real-world practice when heavily-calcified SB needed to be treated a priori, or in a bail-out manner in order not to be lost following bifurcation lesion interventions. Second, intra-vascular imaging was used in some but not all patients. This was due to the calcified characteristics of the SB lesions in which heavy calcification or fibrosis had prevented the imaging catheter or even the smallest balloon catheter from crossing during the pretreatment. Third, in our cath lab, SB RA was open to certified operators but not restricted exclusively to well-experienced SB RA experts. This could account for more complications like SB perforations. As SB RA is technical-demanding and requires good cooperation between operators and assistants, especially in extremely difficult cases (e.g., those with shallow wire landing zones, extreme heavy calcification, tortuous SB, and in whom more than one burrs were needed for SB RA). Assigning the procedure to well-experienced hands would reduce in-procedure complications, expedite the procedure, and enhance the outcomes. Finally, although our study was the largest cohort to date for SB RA, the study group was relatively small. Whether the strategy of our study with favorable outcomes could be adopted by other institutes is to be confirmed in larger population or in well-designed randomized trials.
| CONCLUSIONS
It was feasible to carry out RA on complex and heavily calcified SB in non-left main bifurcation lesions in a priori or bail-out manner for treatment or preservation in real-world practice in the DES era. The outcome was high success rates with acceptable incidences of complications and long-term MACE. However, it was associated with more SB perforations and higher rates of acute CIN. SB RA should therefore be conducted by well-experienced operators.
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